Subcutaneous Lanalumab in Primary Sjögren's Syndrome
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
Lancet 2021 Nov 30;[EPub Ahead of Print], SJ Bowman, R Fox, T Dörner, et alFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.